JP2024543983A - がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体 - Google Patents

がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体 Download PDF

Info

Publication number
JP2024543983A
JP2024543983A JP2024532556A JP2024532556A JP2024543983A JP 2024543983 A JP2024543983 A JP 2024543983A JP 2024532556 A JP2024532556 A JP 2024532556A JP 2024532556 A JP2024532556 A JP 2024532556A JP 2024543983 A JP2024543983 A JP 2024543983A
Authority
JP
Japan
Prior art keywords
alkyl
group
hydrogen
membered heterocyclyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543983A5 (https=
Inventor
ブロカー，ヨアヒム
アボット，ジェイソン
ツイ，ジェンウェン
フェシク，スティーヴン・ダブリュー
フックス，ユリアン
ゴウルナー，アンドレアス
ヘルデイス，ローレンツ
ホッジズ，ティム
リトル，アンドリュー
マントゥリディス，アンドレアス
ファン，ジェイソン
サルカール，ドルバ
スメスルスト，クリスティアン・アラン・パウル
スン，チー
ウォーターソン，アレックス
ヴュンベルク，トビアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2024543983A publication Critical patent/JP2024543983A/ja
Publication of JP2024543983A5 publication Critical patent/JP2024543983A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024532556A 2021-12-01 2022-11-30 がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体 Pending JP2024543983A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284778P 2021-12-01 2021-12-01
US63/284,778 2021-12-01
PCT/EP2022/083936 WO2023099612A1 (en) 2021-12-01 2022-11-30 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024543983A true JP2024543983A (ja) 2024-11-26
JP2024543983A5 JP2024543983A5 (https=) 2025-11-28

Family

ID=84536000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532556A Pending JP2024543983A (ja) 2021-12-01 2022-11-30 がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体

Country Status (6)

Country Link
US (1) US20250296940A1 (https=)
EP (1) EP4441053A1 (https=)
JP (1) JP2024543983A (https=)
CN (2) CN118574835A (https=)
TW (1) TW202340209A (https=)
WO (1) WO2023099612A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
JP7808058B2 (ja) 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024246099A1 (en) * 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2024255795A1 (en) * 2023-06-14 2024-12-19 Insilico Medicine Ip Limited Kras inhibitors and uses thereof
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
CN121620514A (zh) 2023-08-02 2026-03-06 耐瑞欧医疗公司 蛋白质酪氨酸磷酸酶降解剂及其用途
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
US20250205238A1 (en) 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
CN117946135A (zh) * 2024-01-24 2024-04-30 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
CN117924327A (zh) * 2024-01-24 2024-04-26 上海湃隆生物科技有限公司 具有大环结构的Kras抑制剂化合物
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025190158A1 (zh) * 2024-03-14 2025-09-18 四川科伦博泰生物医药股份有限公司 螺环化合物、其制备方法及用途
WO2025190342A1 (zh) * 2024-03-15 2025-09-18 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
WO2025201480A1 (zh) * 2024-03-28 2025-10-02 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025261393A1 (en) * 2024-06-19 2025-12-26 Insilico Medicine Ip Limited Novel compounds as kras inhibitors and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026007740A1 (zh) * 2024-07-04 2026-01-08 四川科伦博泰生物医药股份有限公司 螺环化合物、其制备方法及用途
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015785A1 (en) * 2024-07-12 2026-01-15 Blossomhill Therapeutics, Inc. Spirocyclic kras inhibitors for treating disease
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
CN119751476B (zh) * 2025-03-05 2025-06-03 苏州共康医药科技有限公司 螺环类化合物及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
MX2021000887A (es) * 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
PT3886991T (pt) * 2019-12-11 2022-10-17 Lilly Co Eli Inibidores de kras g12c
UY39129A (es) 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
JP7808058B2 (ja) 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体

Also Published As

Publication number Publication date
US20250296940A1 (en) 2025-09-25
WO2023099612A1 (en) 2023-06-08
CN118647620A (zh) 2024-09-13
EP4441053A1 (en) 2024-10-09
CN118574835A (zh) 2024-08-30
TW202340209A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
US12545670B2 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024543983A (ja) がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
JP2024543982A (ja) がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
EP4441054A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441055A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441050A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP7189956B2 (ja) Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
HK40097417A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222B (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251119